scholarly journals Stilbene Analogs of Resveratrol Improve Insulin Resistance through Activation of AMPK

2013 ◽  
Vol 77 (6) ◽  
pp. 1229-1235 ◽  
Author(s):  
Tomomi ITO-NAGAHATA ◽  
Chiaki KURIHARA ◽  
Miki HASEBE ◽  
Akiko ISHII ◽  
Kaori YAMASHITA ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Improve Insulin Resistance ◽  
Stilbene Analogs

scholarly journals Effect of carvedilol versus nebivolol on insulin resistance among non-diabetic, non-ischemic cardiomyopathy with heart failure

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Yasser Gaber Metwally ◽  
Heba Kamal Sedrak ◽  
Inass Fahiem Shaltout
Keyword(s):  
Heart Failure ◽  
Insulin Resistance ◽  
Insulin Sensitivity ◽  
Ischemic Cardiomyopathy ◽  
Diabetic Patients ◽  
Promising Strategy ◽  
Improve Insulin Resistance ◽  
First Choice ◽  
The Difference

Abstract Background Although B-blockers provide unequivocal benefits in heart failure (HF) management, some B-blockers worsen insulin resistance. It will be a promising strategy to recruit such a B blocker that did not worsen or can even improve insulin resistance (IR). So, this study aimed to assess the effect of two of the third-generation B-blockers (carvedilol versus nebivolol) on insulin sensitivity state in non-diabetic patients with non-ischemic cardiomyopathy with heart failure. Results Out of 43 patients enrolled, 58.1% represented the carvedilol group while 41.9% represented the nebivolol group. Nebivolol improves insulin resistance-related variables (fasting glucose, fasting insulin, and HOMA-IR; P < 0.001, 0.01, and 0.01 respectively). The percentage of change at homeostasis model of assessment (HOMA-IR), indicative of insulin sensitivity status, between baseline versus at 3-months follow-up level of intra-group comparison was increased by 4.58% in the carvedilol arm whereas it was decreased by 11.67% in the nebivolol arm, and the difference on the intragroup level of comparison was significant (P < 0.001 and 0.01 respectively). Conclusion Nebivolol improves insulin resistance-related variables .Nebivolol may be recommended as the B blocker of the first choice for those with non-ischemic cardiomyopathy heart failure with evident insulin resistance; however, larger scaled prospective multicenter randomized trials are needed for confirming our favorable results.

scholarly journals Rice Bran Protein Hydrolysates Improve Insulin Resistance and Decrease Pro-inflammatory Cytokine Gene Expression in Rats Fed a High Carbohydrate-High Fat Diet

Nutrients ◽  
2015 ◽  
Vol 7 (8) ◽  
pp. 6313-6329 ◽  
Author(s):  
Kampeebhorn Boonloh ◽  
Veerapol Kukongviriyapan ◽  
Bunkerd Kongyingyoes ◽  
Upa Kukongviriyapan ◽  
Supawan Thawornchinsombut ◽  
...  
Keyword(s):  
Gene Expression ◽  
Insulin Resistance ◽  
Rice Bran ◽  
High Fat Diet ◽  
Inflammatory Cytokine ◽  
Cytokine Gene Expression ◽  
Cytokine Gene ◽  
High Fat ◽  
High Carbohydrate ◽  
Improve Insulin Resistance

Physical Education Can Improve Insulin Resistance

2013 ◽  
Vol 45 (10) ◽  
pp. 1956-1964 ◽  
Author(s):  
RICHARD DAVID TELFORD ◽  
ROSS B. CUNNINGHAM ◽  
ROHAN M. TELFORD ◽  
ROBIN M. DALY ◽  
LISA S. OLIVE ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Physical Education ◽  
Improve Insulin Resistance

scholarly journals Blocking IL-6 trans-Signaling Prevents High-Fat Diet-Induced Adipose Tissue Macrophage Recruitment but Does Not Improve Insulin Resistance

2015 ◽  
Vol 21 (3) ◽  
pp. 403-416 ◽  
Author(s):  
Michael J. Kraakman ◽  
Helene L. Kammoun ◽  
Tamara L. Allen ◽  
Virginie Deswaerte ◽  
Darren C. Henstridge ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Adipose Tissue ◽  
High Fat Diet ◽  
High Fat ◽  
Tissue Macrophage ◽  
Macrophage Recruitment ◽  
Adipose Tissue Macrophage ◽  
Improve Insulin Resistance

Use of Farnesoid X Receptor Agonists to Treat Nonalcoholic Fatty Liver Disease

2015 ◽  
Vol 33 (3) ◽  
pp. 426-432 ◽  
Author(s):  
Arun J. Sanyal
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Bile Acids ◽  
Fatty Liver Disease ◽  
Animal Studies ◽  
Farnesoid X Receptor ◽  
Nonalcoholic Fatty Liver ◽  
Improve Insulin Resistance

Nonalcoholic fatty liver disease is a common cause of liver related morbidity and mortality. It is closely linked to underlying insulin resistance. It has recently been shown that bile acids modulate insulin signaling and can improve insulin resistance in cell based and animal studies. These effects are mediated in part by activation of farnesoid x receptors by bile acids. In human studies, FXR agonists improve insulin resistance and have recently been shown to improve NAFLD. The basis for the use of FXR agonists for the treatment of NAFLD and early human experience with such agents is reviewed in this paper.

Sign in / Sign up

Export Citation Format

Share Document